{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:19Z","timestamp":1790263159985,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Vela Diagnostics Europe"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jcv.2019.104207","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T02:40:58Z","timestamp":1572748858000},"page":"104207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1106-9826","authenticated-orcid":false,"given":"Enagnon Kazali","family":"Alidjinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Coulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hallaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Meybeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Huleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Ajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-2074","authenticated-orcid":false,"given":"Didier","family":"Hober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bocket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2019.104207_bib0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcv.2016.07.007","article-title":"Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA","volume":"82","author":"Zaccarelli","year":"2016","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.jcv.2019.104207_bib0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431093","article-title":"Proviral DNA as a target for HIV-1 resistance analysis","volume":"58","author":"L\u00fcbke","year":"2015","journal-title":"Intervirology"},{"key":"10.1016\/j.jcv.2019.104207_bib0015","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/jac\/dkw146","article-title":"Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate combination","volume":"71","author":"Lambert-Niclot","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2019.104207_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2017.10.016","article-title":"Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy","volume":"251","author":"Allavena","year":"2018","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2019.104207_bib0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2019.104207_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"ANRS 138-EASIER study group, Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2019.104207_bib0035","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/JVI.79.3.1975-1980.2005","article-title":"GA hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo","volume":"79","author":"Kieffer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2019.104207_bib0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/JCM.00030-16","article-title":"Deep sequencing of HIV-1 RNA and DNA in newly diagnosed patients with baseline drug resistance showed no indications for hidden resistance and is biased by strong interference of hypermutation","volume":"54","author":"Dauwe","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.104207_bib0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/365671a0","article-title":"Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing","volume":"365","author":"Larder","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2019.104207_bib0050","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","article-title":"Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis","volume":"43","author":"Palmer","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.104207_bib0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jmv.21390","article-title":"French Pediatric Cohort Study ANRS-CO 01 Group, LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)","volume":"81","author":"Avettand-F\u00e8no\u00ebl","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2019.104207_bib0060","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/cid\/cit125","article-title":"Clinical implications of HIV-1 minority variants","volume":"56","author":"Li","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.jcv.2019.104207_bib0065","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/cix1070","article-title":"French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 resistance study group, impact of human immunodeficiency virus type 1 minority variants on the virus response to a rilpivirine-based first-line regimen","volume":"66","author":"Raymond","year":"2018","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.jcv.2019.104207_bib0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/418144a","article-title":"Recombination: multiply infected spleen cells in HIV patients","volume":"418","author":"Jung","year":"2002","journal-title":"Nature."},{"key":"10.1016\/j.jcv.2019.104207_bib0075","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/jvi.66.9.5642-5645.1992","article-title":"Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen","volume":"66","author":"Delassus","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2019.104207_bib0080","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00105-18","article-title":"Comparison of an in vitro diagnostic next-generation sequencing assay with Sanger sequencing for HIV-1 genotypic resistance testing","volume":"56","author":"Tzou","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.104207_bib0085","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jac\/dky003","article-title":"HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform","volume":"73","author":"Raymond","year":"2018","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219302379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219302379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:11:08Z","timestamp":1761361868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653219302379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":17,"alternative-id":["S1386653219302379"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2019.104207","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2019.104207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104207"}}